恶性脑胶质瘤

  • 网络glioblastoma
恶性脑胶质瘤恶性脑胶质瘤
  1. 免疫赋活剂OK(432)抗恶性脑胶质瘤的实验研究及临床疗效初步观察

    The Effect of OK_ ( 432 ) on Malignant Cerebral Glioma

  2. 人参皂甙与IL-2协同诱导PBMC对恶性脑胶质瘤细胞杀伤活性研究

    Cytotoxicity of GS and IL-2 Activated PBMC to Malignant Glioma Cells

  3. 替尼泊甙-司莫司汀序列给药治疗恶性脑胶质瘤免疫赋活剂OK(432)抗恶性脑胶质瘤的实验研究及临床疗效初步观察

    Clinical analysis of sequential chemotherapy with VM26-MeCCNU for malignant brain glioma The Effect of OK_ ( 432 ) on Malignant Cerebral Glioma

  4. 本文研究探讨在体内外基因转移Fas配体和/或P21~(WAF1/CIP1)过量表达对恶性脑胶质瘤治疗的影响。

    To evaluate effects of gene transfer FasL and br P21 WAFI / CIP1in vitro and in vivo for treatment of human malignant gliomas .

  5. CD3AK细胞治疗恶性脑胶质瘤体外实验

    Experimental study on adoptive immunotherapy for glioma with CD3AK cells

  6. PHA、CD3、与IL-2协同诱导PBMC过继免疫治疗恶性脑胶质瘤的实验研究

    Experimental study on adoptive immunotherapy for malignant glioma with peripheral blood mononuclear cells ( PBMC ) Induced by PHA , CD3 and IL-2

  7. 目的探讨胞嘧啶脱氨酶(CD)自杀基因转染U251恶性脑胶质瘤细胞的方法及其表达效果。

    Objective To explore the methods of cytosine deaminase ( CD ) suicide gene transfection and its expression in U251 malignant brain glioma cells .

  8. 体外药敏实验及MGMT表达为依据的恶性脑胶质瘤个体化化疗:42例近期疗效分析

    Individualized Chemotherapy Based on Drug Sensitivity and Resistance Assay and MGMT Protein Expression for Patients with Malignant Glioma & Analysis of 42 Cases

  9. 结论:恶性脑胶质瘤术后ACNU间质化疗联合同步放疗是一个安全有效的较佳选择治疗方案。

    Conclusions Postoperative ACNU interstitial chemotherapy concurrent with radiotherapy for malignant gliomas is a safe , effective and alternative therapeutic plan .

  10. 目的:通过回顾性分析研究恶性脑胶质瘤手术后采用现代三维立体适形放疗(3D-CRT)联合替莫唑胺(TMZ)化疗综合治疗的疗效。

    Objective : To observe the curative efficacy of three-dimensional conformal radiotherapy ( 3D-CRT ) combined with temozolomide ( TMZ ) treatment for malignant glioma after surgery by retrospective analysis .

  11. 目的探讨替尼泊甙(VM26)与司莫司汀(MeCCNU)序列给药治疗恶性脑胶质瘤的疗效及其并发症的防治。

    Objective To investigate the effect of sequential chemotherapy with VM26 and MeCCNU in treating malignant brain glioma and to explore measures to prevent and treat complications .

  12. 结果高度恶性脑胶质瘤MIBI摄取指数为1.9~6.6(平均3.6±1.4),低度恶性胶质瘤为0.8~1.7(1.1±0.2),两组比较P<0.01。

    Results In high - grade malignant gliomas , the MIBI uptake index was 1.9 ~ 6.6 ( mean 3.6 ± 1.4 ), low grade malignant gliomas was 0.8 ~ 1.7 ( 1.1 ± 0.2 ), there is a comparison between the two groups ( P < 0.01 ) .

  13. 手术加序列化疗治疗恶性脑胶质瘤的临床研究

    Clinical Study of Operation Following by Chemotherapy on Malignant Gliomas

  14. 术后选择性化疗联合瘤内近距离放疗治疗成人恶性脑胶质瘤

    Selective chemotherapy combined with brachytherapy in treatment of malignant glioma after surgery

  15. 21例恶性脑胶质瘤术后三维适形放射治疗临床观察

    Clinical Observation of Postoperative 3-dimensional Conformal Radiotherapy in 21 Cases with Malignant Gliomas

  16. 恶性脑胶质瘤术后嘧啶亚硝脲间质化疗同步放疗临床观察

    Clinical observation on postoperative ACNU interstitial chemotherapy concurrent with radiotherapy for malignant gliomas

  17. 恶性脑胶质瘤分子靶向治疗研究进展

    Advances of Molecular Targeted Therapy for Malignant Gliomas

  18. 替莫唑胺治疗难治性恶性脑胶质瘤临床观察

    Clinical study of temozolomide for refractory malignant glioma

  19. 恶性脑胶质瘤局部治疗新技术及疗效观察

    Observe on the Curative Effect of New Local Treatment Technic in Malignant Encephalic Glioma

  20. 显微手术后间质化疗联合增敏放疗治疗恶性脑胶质瘤

    Treatment of malignant brain gliomas using interstitial chemotherapy combined with sensitive radiotherapy after microsurgical excision

  21. 大鼠增殖抑制基因表达变化与恶性脑胶质瘤生长的关系

    The relationship between the expression of hyperplasia suppressor gene and growth of malignant glioma in rats

  22. 目的:恶性脑胶质瘤是人头颈部常见的原发性恶性肿瘤。

    Objective : Malignant glioma is one of the most common primary malignant tumor in head and neck .

  23. 总结恶性脑胶质瘤病人口服化疗药物替莫唑胺的护理体会。

    Objective : To summarize experiences of nursing care of malignant brain neurogliocytoma patients undergoing perioral temozolomide as chemotherapy .

  24. 蛇枝黄苓汤联合放疗同步治疗恶性脑胶质瘤的临床研究

    Clinical Study on She Zhi Huang Ling Decoction Combined with Radiotherapy in the Treatment of Postoperative Patients with Malignant Glioma

  25. 目的证明多聚体缓释化疗治疗高度恶性脑胶质瘤的有效性和安全性。

    Objective To evaluated the safety and efficacy of the treatment of malignant brain tumors with implantable slow-release chemotherapeutic polymers .

  26. 结论基因转移P21WAF1CIP1为研究基因治疗恶性脑胶质瘤提供了有效的手段。

    Conclusions Gene transfer P21 WAF1 / CIP1 to therapy for malignant brain tumors would have wide application in the future .

  27. 结论1.我们采用神经干细胞培养方法成功分离了人恶性脑胶质瘤干细胞,并对其多能性和自我更新能力等进行了鉴定。

    We isolated the CSCs of human glioblastoma by culturing in neural stem cells medium and identify the pluripotency and self-renewal of CSCs .

  28. [方法]对26例患有恶性脑胶质瘤病人施行化疗前、化疗中和化疗后的护理。

    Methods : Nursing care was carried out for a total of 26 cases with malignant brain neurogliocytoma before , during and after chemotherapy respectively .

  29. 目的评价含替尼泊苷联合化疗方案对恶性脑胶质瘤的治疗效果和毒副作用,探讨有效的辅助化疗方案,以期提高恶性脑神经胶质瘤患者的疗效,延长生存期。

    Objective It is to evaluate the curative effects and the relevant toxicty and side effets on curing brain malignant neuroglioma by using teniposide combination chemotherapy .

  30. 目的:观察恶性脑胶质瘤术后应用蛇枝黄苓汤联合放疗同步治疗的临床疗效,并探讨该疗法的作用机理。

    Objective : The study is to investigate the effect of Chinese decoction She Zhi Huang Ling Decoction ( SD ) combined with radiotherapy for malignant glioma .